J&J’s Natrecor Out Of Medicare For Chronic Heart Failure
This article was originally published in The Pink Sheet Daily
CMS’ final national coverage determination does not change contractor discretion to cover other off-label uses.
You may also be interested in...
CMS' proposed national coverage determination would not provide Medicare coverage of nesiritide for chronic heart failure.
The Johnson & Johnson subsidiary's program for its congestive heart failure agent includes sales force training and new promotional materials that reflect expert panel recommendations on nesiritide use.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.